摘要
肺癌的基础和临床研究发展迅速。联合化疗可改善老年肺癌患者预后,化疗联合早期姑息治疗可延长晚期患者生存期,新药crizotinib治疗ALK阳性晚期肺癌效果显著,表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)在晚期EGFR突变患者中的一线治疗地位得到确认,立体定向放疗(SBRT)成为早期不可手术患者的首要选择。本文综述2010年相关研究进展。
The basic and clinical studies on lung cancer are developed rapidly. The combined chemotherapy could improve the prognosis of elderly patients with lung cancer. Chemotherapy combining with early palliative treatment could prolong the survival of terminal patients. The new drug crizotinib is of significant efficacy to terminal patients with ALK positive. As a primary the rapentics, the effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors （EGFR-TKIs） in terminal patients with EGFR mutation has been praved. The stereotactic body radiation therapy （SBRT） becomes the first choice for inoperable patients with early stage of lung cancer. This review describes the progress of lung cancer diagnosis and treatment in 2010.
出处
《世界临床药物》
CAS
2011年第2期65-68,共4页
World Clinical Drug
关键词
肺癌
非小细胞
化疗
放疗
lung cancer
non-small cell
drug therapy
radiation therapy
